Takeda opposes purchasers' motion for judgment in US antitrust case over Amitiza
( May 14, 2026, 22:31 GMT | Official Statement) -- MLex Summary: Takeda Pharmaceuticals told a US federal court that Amitiza purchasers are unable to establish that evidence points so strongly and overwhelmingly in their favor that no reasonable jury could have returned an adverse verdict. Takeda opposed a motion for judgment, saying that even if plaintiffs had established that Amitiza prices and profits were overly high, they still can’t prove that output was restricted prior to generic entry.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.